Chemical pathology

Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients

Retrieved on: 
Wednesday, August 4, 2021
Health, Infectious Diseases, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Clinical medicine, Medical specialties, Medicine, Biomarkers, C-reactive protein, Chemical pathology, CAMP receptor protein, CRP Group, the LIVE-AIR, Phase 3 Study of Lenzilumab, Humanigen, Inc., THE LIVE-AIR, PHASE 3 STUDY OF LENZILUMAB, HUMANIGEN, INC.

In the overall population with CRP

Key Points: 
  • In the overall population with CRP
  • LIVE-AIR Phase 3 study met its primary endpoint of survival without ventilation demonstrating a 1.54-fold improvement overall and trended to a 2.68-fold improvement in Black and African-American patients.
  • This study was a randomized, double-blind, placebo-controlled, multi-center Phase 3 trial for the treatment and prevention of serious and potentially fatal outcomes in patients hospitalized with COVID-19 pneumonia.
  • The primary endpoint was the difference between lenzilumab treatment and placebo treatment in SWOV through day 28 following treatment.

InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development

Retrieved on: 
Monday, August 2, 2021
Biotechnology, General Health, Hospitals, Health, Pharmaceutical, Branches of biology, Biology, Life sciences, Glycoproteomics, Proteomics, Biomarkers, Biotechnology, Chemical pathology, Medical signs, Precision medicine

InterVenn Biosciences today announced the completion of a $201 million Series C financing.

Key Points: 
  • InterVenn Biosciences today announced the completion of a $201 million Series C financing.
  • To date, the InterVenn glycoproteomics platform has been used to develop 16 clinical use cases across oncology and other indications.
  • InterVenn Biosciences utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine.
  • For more information about InterVenn Biosciences, please visit the companys website .

Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Health, Clinical trials, Other Health, Medical specialties, Branches of biology, Clinical medicine, Immunology, Antibodies, Chemical pathology, Communication, Forward-looking statement, Anti-SSA/Ro autoantibodies, Vaccine

Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.

Key Points: 
  • Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.
  • The antibody tests can detect antibodies that are generated both from infection by the virus and from the vaccines.
  • Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors.
  • Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law.

Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu

Retrieved on: 
Thursday, July 22, 2021
Clinical medicine, Medicine, Branches of biology, Blood tests, Acute-phase proteins, Chemical pathology, Ortho Clinical Diagnostics, Immunologic tests, Ortho, C-reactive protein, Troponin, IVD

IL-6 is gaining utility in the evaluation of the most severe forms of respiratory distress, one of the causes of poor outcomes for patients suffering inflammatory diseases.

Key Points: 
  • IL-6 is gaining utility in the evaluation of the most severe forms of respiratory distress, one of the causes of poor outcomes for patients suffering inflammatory diseases.
  • Ortho's comprehensive critical care menu also includes tests for hs Troponin, NT-pro BNP, Ferritin, CRP, D-dimer, Lactate, and PCT.
  • Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world's largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.
  • Ortho helps its customers enhance clinical outcomes, improve efficiency, overcome staffing challenges and reduce costs.

Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu

Retrieved on: 
Thursday, July 22, 2021
Clinical medicine, Medicine, Branches of biology, Blood tests, Acute-phase proteins, Chemical pathology, Ortho Clinical Diagnostics, Immunologic tests, Ortho, C-reactive protein, Troponin, IVD

IL-6 is gaining utility in the evaluation of the most severe forms of respiratory distress, one of the causes of poor outcomes for patients suffering inflammatory diseases.

Key Points: 
  • IL-6 is gaining utility in the evaluation of the most severe forms of respiratory distress, one of the causes of poor outcomes for patients suffering inflammatory diseases.
  • Ortho's comprehensive critical care menu also includes tests for hs Troponin, NT-pro BNP, Ferritin, CRP, D-dimer, Lactate, and PCT.
  • Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world's largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.
  • Ortho helps its customers enhance clinical outcomes, improve efficiency, overcome staffing challenges and reduce costs.

908 Devices to Report Second Quarter Financial Results on August 4, 2021

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Chemical pathology, Clinical pathology, Mass spectrometry, Spectrometers, Handheld game console, Science and technology, Science

BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- 908 Devices Inc., (Nasdaq: MASS)a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the second quarter 2021 before market open on Wednesday, August 4, 2021.

Key Points: 
  • BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- 908 Devices Inc., (Nasdaq: MASS)a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the second quarter 2021 before market open on Wednesday, August 4, 2021.
  • Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
  • Live audio of the webcast will be available on the Investors section of the company website at: www.908devices.com .
  • 908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications.

Congenica Receives CE Mark for Genomic Analysis Software

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Emerging technologies, Biomarkers, Chemical pathology, Personalized medicine, Medical device, In vitro, Molecular diagnostics

Cambridge, United Kingdom 21 July 2021 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).

Key Points: 
  • Cambridge, United Kingdom 21 July 2021 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).
  • Medical devices require the CE mark designation for use in clinical applications in several key territories including the UK and the EU.
  • Congenicas world-leading genomic analysis technology platform supports the delivery of personalised medicine at scale, enabling rapid and accurate diagnoses for patients.
  • Congenicas world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.

Congenica Receives CE Mark for Genomic Analysis Software

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Emerging technologies, Biomarkers, Chemical pathology, Personalized medicine, Medical device, In vitro, Molecular diagnostics

Congenica Receives CE Mark for Genomic Analysis Software

Key Points: 
  • Cambridge, United Kingdom 21 July 2021 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).
  • Medical devices require the CE mark designation for use in clinical applications in several key territories including the UK and the EU.
  • Congenicas world-leading genomic analysis technology platform supports the delivery of personalised medicine at scale, enabling rapid and accurate diagnoses for patients.
  • Congenicas world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.

Dosis Survey: Large Majority of Patients Confident About Personalized Medicine

Retrieved on: 
Tuesday, July 20, 2021
Software, Technology, General Health, Health, Articles, Branches of biology, Medicine, Emerging technologies, Biomarkers, Biotechnology, Chemical pathology, Personalized medicine

Research from health technology pioneer Dosis suggests that a large majority (85%) of people believe personalized medicine can enhance care delivery.

Key Points: 
  • Research from health technology pioneer Dosis suggests that a large majority (85%) of people believe personalized medicine can enhance care delivery.
  • Dosis, a personalized dosing platform focused on chronic disease management, surveyed more than 1,000 people, and found that nearly 80% of respondents think personalized medicine should become the standard of care for everyone.
  • Personalized medicine is going to be the standard of care, and our survey suggests a large majority of people want these tools and technologies adopted widely, said Shivrat Chhabra, CEO and co-founder at Dosis.
  • When asked, Do you think personalized medicine should become the standard of care for everyone?, the majority (79%) responded affirmatively.

Clinical Mass Spectrometry Market to reach USD 1.83 billion growth|COVID-19 Impact and Analysis|Technavio

Retrieved on: 
Friday, July 16, 2021
Occupational safety and health, Articles, Health, Medical specialties, Chemical pathology, Mass spectrometry, Spectrometers, COVID-19 pandemic, COVID-19

The report offers a detailed analysis of the impact of the COVID-19 pandemic on the clinical mass spectrometry market in optimistic, probable, and pessimistic forecast scenarios.

Key Points: 
  • The report offers a detailed analysis of the impact of the COVID-19 pandemic on the clinical mass spectrometry market in optimistic, probable, and pessimistic forecast scenarios.
  • COVID-19 Impact Analysis on Clinical Mass Spectrometry Market can now be gained through our report.
  • The clinical mass spectrometry market will witness a Neutral impact during the forecast period owing to the widespread growth of the COVID-19 pandemic.
  • Get report snapshot here to get a detailed market share analysis of market participants during COVID-19 lockdown:
    Clinical Mass Spectrometry Market 2021-2025: Segmentation
    The clinical mass spectrometry market is segmented as below: